Filing Flows › Vanda Pharmaceuticals (VNDA) › Q1 2025
Vanda Pharmaceuticals (VNDA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Vanda Pharmaceuticals (VNDA) reported revenue of $50.0M for the first quarter 2025 (Q1 2025), +5% from a year earlier and -6% from the quarter before. Operating margin was -82.0%, net loss $29.5M (58.9% of revenue).
Vanda Pharmaceuticals, Q1 2025: revenue $50.0M (+5% year over year), operating margin -82.0%, net loss $29.5M, operating cash flow −$33.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $50.0M | -6% | +5% |
| Operating profit | −$41.0M | — | — |
| Net earnings | −$29.5M | — | — |
| Operating cash flow | −$33.1M | — | — |
What changed
Revenue was $50.0M in Q1 2025, up 5% year over year and down 6% from the previous quarter. Fanapt® was the largest line at 47% of revenue. Fanapt® added $3.0M year over year (up 14%), 115% of the total change. PONVORY® net product sales declined 18%.
Operating costs exceeded revenue by $41.0M, an operating margin of -82.0%. Total costs grew 61% against revenue growth of 5%. The fastest-growing cost line was Research & development (+69%). The quarter ended with a net loss of $29.5M, wider than the previous quarter's $4.9M loss.
Operating cash flow was −$33.1M. Non-cash charges added back $2.0M of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $8.6M. Capital expenditures of $436K exceeded it, leaving free cash flow of −$33.6M.
Questions
What was Vanda Pharmaceuticals' revenue in the first quarter 2025?
Vanda Pharmaceuticals (VNDA) reported revenue of $50.0M for the first quarter 2025 (Q1 2025), +5% from a year earlier and -6% from the quarter before.
Was Vanda Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $41.0M (-82.0% of revenue) and net loss $29.5M.